Please provide your email address to receive an email when new articles are posted on . “Although some real-world studies suggest that anti-vascular endothelial growth factor therapy for DME with good ...

Breye is advancing danegaptide to Phase II trials after the drug showed signs of improving disease activity in a Phase Ib ...

Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data ...

The FDA designates Regeneron Pharmaceuticals' (NASDAQ:REGN) Eylea (aflibercept) a Breakthough Therapy (BTD) for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

The Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol S study was a randomized, active-controlled study comparing Lucentis to a type of laser therapy called panretinal or scatter ...

Diabetic macular edema (DME) occurs when fluid accumulates behind the macula, the part of your retina that processes central vision. DME can occur at any stage of diabetic retinopathy (DR). However, ...

The American Society of Retina Specialists provided guidance on the management of nonproliferative and proliferative diabetic retinopathy without diabetic macular edema in an article in Journal of ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

STOCKHOLM -- Nonproliferative diabetic retinopathy (NPDR) had a significantly greater risk of progression and complications in patients who also had obstructive sleep apnea (OSA), a large ...

The Centers for Medicare and Medicaid Services (CMS) will cover an autonomous screening tool and allow it to count toward quality measures. As part of its 2022 Medicare Physician Fee Schedule, CMS set ...